ganda’s pharmaceutical industry sits at the intersection of two national priorities: industrialization and public health security. Yet despite years of government support, local manufacturers continue to supply only a small fraction of the country’s medicine needs, leaving Uganda heavily dependent on imported drugs.
The numbers illustrate the scale of the challenge. In 2025, Uganda imported medicaments worth approximately USD 699.5 million, with India remaining the country’s largest supplier of affordable generic medicines. Although local production has expanded over the past decade, imported medicines still account for between 80% and 90% of national demand, depending on the category and measurement methodology.
The outcome is a striking contradiction. Uganda has spent years promoting pharmaceutical self-sufficiency through initiatives such as Buy Uganda Build Uganda (BUBU), tax incentives, subsidized industrial land, and preferential procurement policies. Yet the country remains overwhelmingly reliant on foreign manufacturers for many of its essential medicines.
The question is no longer whether Uganda wants a stronger pharmaceutical sector. The question is why progress has remained so limited despite sustained policy support.
A Sector Growing Below Its Potential
Uganda’s pharmaceutical market continues to expand, driven by rapid population growth, increased healthcare access, and persistent disease burdens including malaria, HIV/AIDS, tuberculosis, and a growing incidence of non-communicable diseases.
The country currently has between 14 and 21 licensed pharmaceutical manufacturers, although only a handful operate at significant commercial scale and meet international Good Manufacturing Practice standards.
Among the sector’s leading success stories is Quality Chemical Industries Limited (QCIL), whose Luzira-based facility produces HIV/AIDS and malaria medicines for domestic and regional markets. The company has built annual production capacity exceeding 1.4 billion tablets and capsules and plans to expand further.
Yet even with such investments, local manufacturers collectively account for only about 10% of the market. Most production remains concentrated in secondary manufacturing activities such as formulation, packaging, and tableting rather than the production of pharmaceutical ingredients themselves.
As a result, Uganda’s pharmaceutical sector remains dependent on foreign supply chains long before medicines reach local factories.
The Missing Chemical Foundation
The most significant structural weakness lies in the absence of domestic production of Active Pharmaceutical Ingredients (APIs), the chemical compounds that make medicines effective.
Across Africa, more than 95% of APIs are imported, largely from India and China. Uganda follows the same pattern.
Local manufacturers import nearly all the raw materials required to produce medicines before processing them into finished products. This dependence exposes firms to shipping costs, exchange-rate fluctuations, customs expenses, and transport challenges associated with operating in a landlocked economy.
The consequence is a structural cost disadvantage.
While policymakers often view local manufacturing as a pathway toward cheaper medicines, imported generic drugs frequently arrive in Uganda at lower prices than locally manufactured alternatives. Large Asian producers benefit from integrated supply chains, enormous production volumes, and decades of industrial specialization that significantly reduce costs.
For Ugandan manufacturers, competing against these advantages remains extremely difficult.
Capital Constraints Continue to Limit Expansion
Financing represents another major obstacle.
Pharmaceutical manufacturing requires substantial investment in production facilities, quality-control laboratories, clean-room environments, regulatory compliance systems, and specialized equipment.
Many local firms struggle to access affordable long-term financing needed to support such investments. Commercial lending rates remain relatively high, while industrial financing options are limited.
This financing gap directly affects competitiveness.
Without access to patient capital, manufacturers often lack the resources required to expand production, modernize facilities, obtain international certifications, or undertake research and development. Consequently, many firms remain too small to achieve economies of scale capable of lowering production costs.
The result is a sector caught in a cycle where limited scale constrains profitability, and limited profitability constrains expansion.
Infrastructure and Operational Costs Add Pressure
Manufacturing medicines requires reliable infrastructure.
Consistent electricity supply, high-quality water systems, laboratory testing facilities, cold-chain logistics, and efficient transport networks all play critical roles in pharmaceutical production.
Yet infrastructure challenges continue to raise operating costs across the sector.
Many manufacturers maintain backup power systems to compensate for electricity disruptions. Additional expenditure on water treatment, storage, and transportation further increases production costs.
These expenses ultimately reduce the competitiveness of locally manufactured medicines relative to imported alternatives.
Why Imports Continue to Dominate
The dominance of imported medicines is not simply the result of domestic shortcomings. It also reflects the strength of international competitors.
Pharmaceutical manufacturers in India and China operate within mature industrial ecosystems characterized by large domestic markets, integrated chemical industries, extensive supplier networks, and lower production costs.
Industry studies indicate that imported generics can be produced at costs between 30% and 50% lower than those achievable by many African manufacturers.
Government interventions have generated measurable gains. Between 2017 and 2019, local production of capsules more than doubled, while oral liquid production increased significantly following policy adjustments and incentive programs.
However, these improvements have not fundamentally altered the market structure.
Imports continue to dominate because the underlying economics still favor foreign producers.
The Public Health Risk Behind the Numbers
The implications extend beyond industrial policy.
Every year, Uganda spends hundreds of millions of dollars importing medicines that could potentially be produced closer to home. These expenditures contribute to foreign exchange outflows while limiting opportunities for domestic job creation and industrial development.
More importantly, dependence on foreign suppliers exposes the country to global disruptions.
The COVID-19 pandemic highlighted the vulnerability of international supply chains. Export restrictions, shipping bottlenecks, geopolitical tensions, and production interruptions can rapidly affect medicine availability in import-dependent markets.
For Uganda, such disruptions carry direct public health consequences.
Access to antimalarials, antiretroviral medicines, antibiotics, and other essential treatments can become vulnerable to events occurring thousands of kilometers away.
In this context, pharmaceutical manufacturing is increasingly viewed not only as an economic issue but also as a strategic national security concern.
The Road to Pharmaceutical Self-Reliance
Industry experts increasingly argue that incremental reforms alone will not transform the sector.
Meaningful progress may require regional collaboration to establish API manufacturing capacity, innovative financing mechanisms to support industrial expansion, stronger partnerships between academia and industry, and greater investment in pharmaceutical research and development.
The East African Community market offers an additional opportunity. Access to a regional consumer base of more than 300 million people could provide the scale necessary to support larger manufacturing investments and attract foreign direct investment.
Successful companies such as QCIL demonstrate that local pharmaceutical manufacturing can succeed when capital, technology transfer, and supportive policy frameworks align.
However, isolated success stories will not be enough to transform the industry.
The Bottom Line
Uganda’s pharmaceutical challenge is not a failure of demand or policy ambition. It is a failure of industrial scale, capital access, and supply-chain integration.
For years, policymakers have sought to reduce reliance on imported medicines. Yet without domestic production of critical raw materials, affordable long-term financing, and globally competitive manufacturing ecosystems, import dependence remains deeply entrenched.
The country’s growing population and expanding healthcare needs will only increase demand for medicines in the years ahead.
Unless structural barriers are addressed, Uganda will continue importing most of the drugs it relies on, leaving one of its most critical sectors dependent on foreign factories and vulnerable to global shocks beyond its control.
